Authorized purpose: IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.
Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Kidneys and other patient-specific surgical anatomy
Key limitation
Keep in mind: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Kidneys and other patient-specific surgical anatomy Input: Supported DICOM images, study metadata, and release-specific user inputs.
Who uses it?Intended users: Qualified imaging professionals and physicians trained for the represented anatomy and workflow.
What does the software produce?Output: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.
What is its most important limitation?Key limitation: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
Clinical takeaway. Clinical role: IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA decision material describes DICOM MR and contrast-enhanced CT input, manual and machine-learning segmentation, kidney CT use for adults with axial slices no thicker than 3 mm, and non-diagnostic rendered output. MR use is manual where the exact package says so.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
IRISeg accepts MR or contrast-enhanced CT images for manual and machine-learning image analysis and segmentation and produces visual three-dimensional models for preoperative planning or intraoperative display; output is non-diagnostic and requires clinician decisions.
Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
The exact FDA decision material describes DICOM MR and contrast-enhanced CT input, manual and machine-learning segmentation, kidney CT use for adults with axial slices no thicker than 3 mm, and non-diagnostic rendered output. MR use is manual where the exact package says so.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA decision material describes DICOM MR and contrast-enhanced CT input, manual and machine-learning segmentation, kidney CT use for adults with axial slices no thicker than 3 mm, and non-diagnostic rendered output. MR use is manual where the exact package says so.
Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K251763 FDA evidence package for IRISeg
DesignFDA software substantial-equivalence decision with image import, segmentation, rendering, usability, and workflow verification
PopulationAdult contrast-enhanced axial kidney CT cases within the labeled slice-thickness limit plus labeled manual MR and surgical-planning workflows
Scopeexact submission
Tested versionIRISeg configuration described in K251763
IndependenceSponsor or vendor study
K251763
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251763 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported DICOM images, study metadata, and release-specific user inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes IRISeg receiving DICOM compliant MR or contrast-enhanced CT images, loading DICOM imaging files and NIfTI segmentation label files from an accessible storage location, and generating an output file used to render virtual segmented 3D models. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "IRISeg is intended for use as a software application that receives DICOM compliant MR or contrast-enhanced CT images" … "IRISeg can open and load CT or MR imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and segmentation label files in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes IRISeg as a segmentation software application running on a general-purpose computer in an office setting, with general-purpose computer host hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "User interface / Graphical user interface design. Same Environment Office setting (Segmentation Software Application running on a general-purpose computer)" … "Host Hardware General-purpose computer Same Compatibility hardware". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes IRISeg as a segmentation software application running on a general-purpose computer in an office setting, with general-purpose computer host hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "User interface / Graphical user interface design. Same Environment Office setting (Segmentation Software Application running on a general-purpose computer)" … "Host Hardware General-purpose computer Same Compatibility hardware". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes IRISeg receiving DICOM compliant MR or contrast-enhanced CT images, loading DICOM imaging files and NIfTI segmentation label files from an accessible storage location, and generating an output file used to render virtual segmented 3D models. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "IRISeg is intended for use as a software application that receives DICOM compliant MR or contrast-enhanced CT images" … "IRISeg can open and load CT or MR imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and segmentation label files in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Intuitive's product security program page describes a coordinated vulnerability disclosure program scoped to its medical devices, supporting software, web services, and mobile applications (reporting to product.security@intusurg.com with PGP), published security advisories with product impact assessments, and a post-market cybersecurity vulnerability monitoring program covering products including da Vinci, Ion, and digital services.
Vendor-wide
Checked 2026-10-27
Vendor statement. Applicant name variants ('Intuitive Surgical Inc.', 'Intuitive Surgical, Inc.') are the identical distinctive name. Exact-release scope is not established.
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, and downtime contract locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. No current vendor source was promoted for this submission.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Outputs supplement accepted interpretation or planning methods and require review against source images; supported modality, anatomy, protocol, patient population, and version limits apply.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. No current vendor source was promoted for this submission.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Synapse PACS 7.6.0 provides medical-image management and processing, including measurements, regional segmentation, clinical calculations, structured reports, comparison, fusion, and volume rendering to aid reading, interpretation, reporting, and treatment planning.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.